In vitro treatment of Idh2R140Q/NHD13 thymocytes with enasidenib, a selective inhibitor of mutant IDH2, led to a marked decrease in leukemic cell proliferation, demonstrating that Idh2R140Q/NHD13 mice could serve as a useful in vivo model for the study of early/immature T cell precursor acute lymphoid leukemia (ALL) development and therapy.
[Cancer Research]
7992332
KAYBYJ2A
items
1
apa
0
default
asc
1
165178
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/